CD4 and candidiasis: In the delayed group, the incidence of candidiasis was significantly higher before therapy was started (13.59 versus 1.42; p-value <0.01), and occurred at a median CD4 T cell count of 259 cells/mm3 (IQR 222–309 cells/mm3).